Given its high prevalence in the general population, which ranges between 5 and 40% in western countries and increases up to 50% in advanced age, sarcopenia is considered a public health problem [4,15]. It causes progressive decline of functional capacity, contributes to frailty, increases the risk of falls and hospitalization in old people [16,17], and leads to poor outcomes in patients with COVID-19 [18]. A large number of pharmacological agents are being tested as anti-sarcopenic agents such as bimagrumab (BYM338), enobasarm (GTx-024), trevogrumab (REGN1033), and sarconeos (BIO101). Most trials are in phase 1 or phase 2 [19]. In addition, outcomes of commonly used treatments (e.g., testosterone, growth hormone, and anabolic steroids) have been rather unsatisfactory [4,20,21,22]. Therefore, the most appropriate strategies for preventing and treating sarcopenia are limited to physical exercise and protein-rich diet [6,21]. Nevertheless, old people tend to be less compliant with physical activity programs [23,24]. Meanwhile, problems of the gastrointestinal (GI) tract that develop during advanced age (e.g., loss of teeth, taste, smell, and decreased absorption) as well as anabolic resistance of aged muscle limit potential benefits of protein-rich food in this group [25,26]. Therefore, it is of importance to search for novel preventive and curative strategies for sarcopenia, which can take into account the multifactorial nature of aging-related skeletal muscle failure.